ANTI-TUMOR ACTIVITY OF DENDRITIC CELLS IN HEALTHY DONORS AND PATIENTS WITH BRAIN TUMORS

In present work, a comparative analysis of cytostatic and cytotoxic activity of IL-4 and IFNα-induced dendritic cells (IL-4- and IFN-DCs) has been performed in healthy donors and patients with brain tumors. Cytostatic activity was evaluated, as a capacity of DCs to inhibit growth of NK-resistant HEp...

Full description

Saved in:
Bibliographic Details
Main Authors: E. R. Chernykh, O. Yu. Leplina, T. V. Tyrinova, M. A. Tikhonova, V. V. Stupak, S. V. Mishinov, I. V. Pendyurin, A. A. Ostanin
Format: article
Language:RU
Published: SPb RAACI 2014
Subjects:
Online Access:https://doaj.org/article/e49c59ecf57c4fe5b2812ddac904fd7f
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In present work, a comparative analysis of cytostatic and cytotoxic activity of IL-4 and IFNα-induced dendritic cells (IL-4- and IFN-DCs) has been performed in healthy donors and patients with brain tumors. Cytostatic activity was evaluated, as a capacity of DCs to inhibit growth of NK-resistant HEp-2 and A-549 tumor cell lines, whereas cytotoxic activity was measured by assessment of HEp-2 lysis. As compared with IL4-DC, IFN-DCs from healthy donors displayed a more pronounced cytostatic effect and similar cytotoxic activity against HEp-2 cells. In the patients with brain tumors, IFN-DCs were characterized by decreased cytotoxic activity. Meanwhile, DCs from the patients with malignant gliomas virtually did not exhibit a cytotoxic potential, whereas IFN-DCs from the patients with benign brain tumors retained their cytotoxic properties. A comparative study has shown that, in contrast to healthy donors, IFN-DCs from the patients with either malignant or benign brain tumors did not inhibit HEp-2 proliferation. The loss of DC-mediated cytostatic activity was not associated with decrease of CD123+ DCs (known as cells with maximal tumor-inhibitory potential), and, most likely, it resulted from functional changes in IFN-DC populations.